From the CEO
Our vision at Pluristem Therapeutics inc. is to leverage our position as the global leader in placenta-based cell science to become the world’s leader in developing and manufacturing cell therapy products. We believe our cutting edge technology can become the standard of care for treating a host of inflammatory and ischemic conditions. We are in the process of achieving this vision by building a successful, winning team to maintain our standard of excellence in the research, development and production of cell therapies.
We continue to develop our understanding surrounding the mechanism of action of PLacental eXpanded (PLX) cells. We then leverage this understanding towards the development of these cells for additional markets. Currently we are actively pursuing indications in the peripheral vascular, pulmonary, orthopedic, ob-gyn and hematology markets.
We also believe “the Process is the Product.” This reflects our view that the precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vitally important to the success of a cell therapy product. Part of the reason we are able to obtain this precision in our cell expansion process is our exclusive ability to expand cells via our proprietary 3D technology. Combining this “Powered by Pluristem” fully automated process with our increasing knowledge of the placental cell is the powerful engine towards identifying additional products for new markets and indications.
Every engine needs a driver, which returns me to the key to success for achieving our vision: the team. Our team has the ability, integrity, commitment and courage to develop breakthrough cell therapies that can transform the treatment of certain diseases and deliver value to our shareholders.
Chairman and CEO